PK/PD: New Microbial Diseases and Model Systems Tawanda Gumbo, MD Associate Professor of Medicine, Division of Infectious Diseases, University of Texas.

Slides:



Advertisements
Similar presentations
PK and Drug Interactions in a Changing World: New Drugs for TB and New Regimens for TB-HIV Co-infection Charles Flexner, MD Johns Hopkins University.
Advertisements

A 23 Variability in the Size of the Fluoroquinolone AUC/MIC for Antibacterial Effect in S.aureus: Impact for Clinical Breakpoints A. R. Noel, K.E. Bowker,
Daniel Everitt, MD; Erica Egizi MPH Global Alliance for TB Drug Development, New York Helen Winter, PhD University of Otago, New Zealand 2012 International.
Scott Butler Infection Innovative Medicines Group AstraZeneca R&D, Boston CPTR Workshop, 2012 Arlington, VA AZD5847 Oxazolidinone for the treatment of.
ANTI-TUBERCULOSIS DRUGS
Pharmacodynamics of MASKO Compounds (Macrolides, Azalides, Streptogramins, Ketolides, and Oxazolidinones) William A. Craig, MD University of Wisconsin.
Animal Model PK/PD: A Tool for Drug Development
Pulmonary TB. BY PROF. AZZA ELMedany Dr. Ishfaq Bukhari.
Population PK/PD analysis of the bactericidal activity of sutezolid and its major metabolite against intracellular Mtb in whole blood cultures of TB patients.
Improvement in Dose Selection Through Clinical Applications of PK/PD in Antimicrobial Drug Development Hartmut Derendorf, Ph.D. University of Florida.
Michael R. Jacobs, MD, PhD Professor of Pathology and Medicine Case Western Reserve University Director of Clinical Microbiology University Hospitals of.
Modeling and Simulation beyond PK/PD CPTR Workshop October 2 – 4, 2012 Pentagon City.
Clinical Pharmacy.  Tuberculosis is caused by M. tuberculosis, an aerobic, non–spore-forming bacillus that resists decolorization by acid alcohol after.
Overview of Use of PK-PD in Streamlining Drug Development William A. Craig Professor of Medicine University of Wisconsin.
Pharmacodynamics of Antibiotics
Part 1 Principles of resistance to antituberculosis drugs Module 10 1.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
Mycobacterium Tuberculosis Amber Garza Kaylee Stroud Jennifer Sanchez.
Pulmonary TB. BY PROF. AZZA EL- MEDANY Department of Pharmacology.
Monte Carlo Simulation Sense and Non-Sense
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
Monte Carlo Simulation
WORK UPS AND MANAGEMENT. Traditional and New Diagnostic Approaches DIAGNOSTICSAPPLICATIONS Traditional approaches - Symptom-based -TST -TB Culture --
Ongoing trials with new drugs/regimens: the fluoroquinolone case J. Grosset, E. Nuermberger & R.Chaisson Center for TB Research, Johns Hopkins University.
PK/PD Modeling in Support of Drug Development Alan Hartford, Ph.D. Associate Director Scientific Staff Clinical Pharmacology Statistics Merck Research.
Application of PK/PD modeling for optimization of linezolid therapy Julia Zayezdnaya Zack.
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
FADDI RAJESH V. DUDHANI, JIAN LI, ROGER L. NATION Facility for Anti-infective Drug Development & Innovation Drug Delivery,
Mutant Prevention Concentration and the Selection Window Hypothesis Karl Drlica, Xilin Zhao, and Tao Lu Public Health Research Institute Newark, NJ.
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
Preclinical Models to Support Dosage Selection
Pharmacokinetics of Antimicrobials in Animals: Lessons Learned William A. Craig, M.D. University of Wisconsin-Madison.
Population PK-PD Modeling of Anti-Infective Agents
The Endpoint from a Resistance Point of View A Symposium to Honor the Career of William A. Craig, M.D. George Drusano, M.D. Co-Director Ordway Research.
Will Personalized Medicine be the clue to eradicate TB?. Pere-Joan Cardona CONFER È NCIA DE L ’ EUROPAN PARLIAMENTARY TECHNOLOGY.
Multiple dosing: intravenous bolus administration
Issues in testing regimens containing multiple novel agents I. Preclinical Testing Jacques Grosset Johns Hopkins University School of Medicine, Baltimore,
Phase I Issues for Novel TB Drugs Dakshina M. Chilukuri, Ph.D. Office of Clinical Pharmacology and Biopharmaceutics, FDA OPEN FORUM ON KEY ISSUES IN TB.
Michael R. Jacobs, MD, PhD FDA Presentation Nov 7, 2001
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
Antibiotic Resistance Emerging antibiotic resistance is a major health concern. 2 million people in the U.S. infected with antibiotic resistant bacteria.
Pulmonary TB. BY PROF.  AZZA ELMedany OBJECTIVES  At the end of lecture, the students should:  Discuss the etiology of tuberculosis  Discuss the.
Role(s) of EBA Studies – Substitute for Dose Ranging JL Johnson, MD Case Western Reserve Univ.
Pharmacodynamic Indices Canisius-Wilhelmina Hospital Nijmegen, The Netherlands Johan W Mouton.
Pk/Pd modelling : Clinical Implications
Pharmacodynamics of Fluoroquinolones G.L. Drusano, M.D. Professor and Director Division of Clinical Pharmacology Clinical Research Institute Albany Medical.
JWM Grindelwald Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands Johan W. Mouton Pharmacodynamic Indices.
Agents for the Treatment of MRSA: Pharmakokinetics &Pharmacodynamics
Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.
Antimycobacterial Drugs September Mycobacteria Mycobacteria are intrinsically resistant to most antibiotics. Because they grow slowly compared with.
Antituberculous treatment.
Dose and range (mg/kg body weight)
Treatment algorithm for tuberculosis
Identification of optimal dose and dosing regimen of clofazimine for the treatment of multi-drug resistant tuberculosis (MDR-TB) based on pharmacokinetic.
Evaluation of the Efficacy of Intramuscular (IM) Administration of Ceftaroline (CPT) Against a Methicillin-Resistant Staphylococcus aureus (MRSA) Strain.
Latent Infection In the nonimmune (susceptible) host, the bacilli initially multiply unopposed by normal host defense mechanisms. The organisms are then.
Pharmacodynamics of novel Mycobacteria tuberculosis DNA gyrase inhibitors EMMANUEL MOYO.
Part 1 Principles of resistance to antituberculosis drugs
W.W. Hope, G.L. Drusano  Clinical Microbiology and Infection 
P1257 Pharmacodynamics of Amikacin Inhale studied in an in vitro pharmacokinetic model of infection KE Bowker, AR Noel, SG Tomaselli, MLG Attwood, AP.
Antibiotic Resistance Emerging antibiotic resistance is a major health concern. 2 million people in the U.S. infected with antibiotic resistant bacteria.
Thomas P. Lodise, PharmD, G.L. Drusano, MD  Critical Care Clinics 
Pharmacokinetics and pharmacodynamics of fluoroquinolones
Principles of Antimicrobial Therapy
E.C. Böttger  Clinical Microbiology and Infection 
Hollow Fiber Infection Model for Antibiotic PK/PD
M.R. Jacobs  Clinical Microbiology and Infection 
TUBERCULOSIS Pulmonary TB Drug therapy Dr. Ishfaq Dr. Aliah.
Fig. 2 Exposure effect screening study of CAV against Mtb.
Principles of Antimicrobial Therapy
Presentation transcript:

PK/PD: New Microbial Diseases and Model Systems Tawanda Gumbo, MD Associate Professor of Medicine, Division of Infectious Diseases, University of Texas Southwestern Medical Center, Dallas, Texas

Log-phase growth bacilli (LPG) : Killed rapidly by INH during early bactericidal activity. Termed BACTERICIDAL effect. Slowly replicating bacilli under acidic conditions (SRB ): Killed by PZA during ~8 weeks of therapy. Believed mostly in macrophages Non-replicating persistent bacilli (NRP): Killed by rifamycins during short bursts of metabolism but needs up to 6 months to be eradicated. Size SRB>>NRP Mitchison’s three population model hypothesis Mitchison DA. The basic mechanisms of chemotherapy. Chest 1979; 76:

Models for PK/PD work in TB Require that one of each of the three Mtb populations be emulated Require that free drug pharmacokinetics of anti-TB at site of infection be correctly recapitulated Mouse models traditionally used. However, it is becoming clear that the bacillary populations in mice are different from cavitary TB

M. tuberculosis in the hollow fiber system Gumbo T, et al. J Infect Dis 2006;195:

GROWTH OF MYCOBACTERIUM TUBERCULOSIS IN THE HOLLOW FIBER SYSTEM: log-phase growth population 5 week experiment 10 4 initial inoculum Log-phase growth pattern during days 1 through 8 Bacterial burden relatively stable thereafter

Isoniazid has the greatest bactericidal activity, but ceases to kill after 2-3 days, believed due to depleting M. tuberculosis in log phase growth ISONIAZID Background

Is the cessation of isoniazid microbial kill due to depletion of M. tuberculosis in exponential growth phase? ISONIAZID Questions

Slow and fast acetylators simulated Doses studied for each acetylation phenotype: –0, 25, 100, and 300 mg a day In addition, a dose of 600 mg a day for fast acetylators ISONIAZID AGAINST M. TUBERCULOSIS Experimental Design

ISONIAZID AGAINST M. TUBERCULOSIS Resistance, Not Extinction Responsible For Effect Cessation Gumbo T, Louie A, Liu W, Bhavnani S, Ambrose P,Brown D, Drusano GL. (2006). Journal of Infectious Diseases 195:

PZA dose-effect & dose scheduling studies All media acidified to pH 5.8 for entire study, and Mtb grew slowly in the HFS, to simulate SRB under acidic conditions Half-life =11hr Doses mimicked: 0, 7.5, 15, 30, 60, 90, 120 mg/kg daily for 28 days (dose effect) EC 20, EC 40, EC 60 then examined in dose-scheduling studies Checked microbial kill and actual PK parameters achieved

Relationship between PZA AUC/MIC and kill The PK/PD index most closely associated with pyrazinamide sterilizing effect was AUC/MIC E=6.52-(2.89 x AUC/MIC AUC/MIC 1.21 r 2 =0.93; p<0.01

BIG QUESTION Where in pulmonary lesions is this large population that PZA kills? –The majority, starting with Mackeness & McDermott in the 1950s and 1960s believe it is within macrophages Few voices here and there: extra-cellular

Rates of sterilizing effect with standard dosing Standard dose of 2grams PZA per day in patients produces 0.1 log 10 CFU/ml/day in 90% of patients From our inhibitory sigmoid E max relationship, the AUC 0-24 /MIC associated with such a kill rate of 0.1log 10 CFU/ml/day is 120

Population PK data 100,000 patients simulated using ADAPT II & ADAPT 5 Pop PK: Wilkins J et al. Eur. J Clin. Pharmacol. 2006; 62 : –Serum clearance= 3.4 L/h, Volume=30 L. PZA penetration in ELF and alveolar macrophages Conte et al. Antimicrob. Agents Chemother. 1999; 43, Alveolar macrophage/serum ratio=0.52 to 1.14 Epithelial lining fluid/serum ratio= MICs at pH 5.8 : Salfinger M & Heifets LB. Antimicrob Agents Chemother 1988;32:

Monte Carlo simulation assuming intracellular location MCS targeting alveolar macrophage PZA concentration associated with AUC 0-24 /MIC of 120. Processing…. Processing… Processing…. …..in 0.07% of patients! But we know that 2G of pyrazinamide has good sterilizing effect rates in patients.

Monte Carlo simulation assuming extracellular location MCS targeting ELF associated with AUC 0-24 /MIC of 120. Processing…. Processing… Processing…. …..in % of patients! Match!

PZA conclusions Based on these simulations, seems that the majority opinion is in this case likely incorrect In fact, in reviewing Robert Koch’s autopsy reports that he published, he commented that most Mtb in pulmonary cavities was extracellular

Wasana Siyambalapitiyage, Crystal Norton, Sandirai Musuka, Shashikant Srivasatava, Carleton Sherman